Cell Freezing Media for Cell Therapy Market Overview
The global cell freezing media for cell therapy market was valued at USD 143.9 million in 2025 and is forecast to reach USD 488.5 million by 2035, expanding at a CAGR of 13.0% during 2026-2035. The forecast covers formulated cryopreservation media and qualified freezing solutions used to preserve therapeutic cells, starting material, intermediates, master and working cell banks, and final cell-therapy products. It excludes cryogenic freezers, storage tanks, shipping containers, general cell-culture media and media sold solely for assisted reproduction or non-therapeutic research.
Freezing media has moved from a laboratory consumable to a critical process material. A formulation can affect post-thaw recovery, viability, phenotype, potency, and the reproducibility of a manufactured dose. These effects become commercially significant when a therapy moves from a small investigator-led study to multicenter trials or commercial production. Developers must then control the formulation, raw-material source, manufacturing site, container, fill volume, shipping condition, and thaw procedure as part of a validated process.
The market is shifting toward serum-free, protein-free, animal-origin-free, and chemically defined formulations. These products reduce biological variability and simplify the assessment of adventitious-agent risk. Dimethyl sulfoxide remains the principal cryoprotectant in clinical cell processing, commonly at 5% or 10%, but its exposure limits, wash requirements, and potential toxicity are driving work on lower-DMSO and DMSO-free systems. Commercial selection now depends on cell-specific recovery and potency data, regulatory documentation, supply assurance and compatibility with closed fill-finish systems-not only survival immediately after thawing.
Autologous CAR-T manufacturing currently creates high-value demand because each patient batch must be protected across collection, processing, final formulation, shipment and administration. Allogeneic therapies could produce a larger volume opportunity as programs scale master banks and off-the-shelf doses. Induced pluripotent stem cell, mesenchymal stromal cell, hematopoietic stem cell, natural killer cell and tumor-infiltrating lymphocyte programs add distinct preservation requirements. No single formulation performs identically across these cell types, leaving room for both standardized products and application-specific media.
Key Highlights
- Global revenue is estimated at USD 143.9 million in 2025 and forecast to reach USD 488.5 million by 2035.
- The market is projected to expand at a CAGR of 13.0% from 2026 through 2035.
- Serum-free and animal-origin-free media account for an estimated 68% of 2025 revenue, equal to USD 97.9 million.
- Immune-cell therapies lead application demand with an estimated 43% share, or USD 61.9 million.
- Pharmaceutical and biotechnology companies generate an estimated 57% of market revenue, equal to USD 82.0 million.
- North America holds an estimated 46% share, while Asia-Pacific is forecast to record the fastest regional growth.
- The United States represents an estimated 39% of global revenue, followed by China at 12%, Germany at 8% and Japan at 7%.
- Supplier qualification, comparability evidence and continuity of GMP supply determine commercial adoption.
Strategic Takeaways
- Cryopreservation media should be qualified as a critical raw material early in development.
- Serum-free and defined formulations will take share from FBS-containing laboratory recipes.
- Post-thaw potency is a stronger differentiator than viability alone.
- Commercial-scale supply agreements will favor vendors with change-control and regulatory support.
- Closed bags and ready-to-use formats can reduce contamination and compounding risk.
- Allogeneic production will increase volume demand and cell-bank standardization.
- Lower-DMSO formulations need therapy-specific clinical evidence before broad substitution.
A Market Being Rewritten by Process Control
Cell therapies are living products, and freezing is not a neutral pause in manufacturing. Ice formation, osmotic stress, cell dehydration and cryoprotectant exposure can alter cell membranes and biological function. A successful process must control the cooling rate, formulation, hold time, final cell concentration, container geometry, storage temperature and thaw profile. Variation in any of these factors may reduce recovery or change a critical quality attribute.
This risk changes purchasing behavior. Research teams may initially prepare a basal medium with fetal bovine serum and DMSO, but that approach becomes harder to defend during clinical development. Sponsors increasingly choose a pre-formulated product with documented component quality, sterility, endotoxin testing, lot release, change notification and access to a drug master file or supporting regulatory package. The supplier is then embedded in the sponsor's chemistry, manufacturing and controls strategy.
The cost of switching is high after clinical validation. A new medium can require comparability studies covering viability, recovery, identity, phenotype, potency and stability. A sponsor may also need to revise batch records, shipping validation and regulatory filings. This creates durable revenue for qualified suppliers, but it also raises the standard for winning a program. Free samples can open an evaluation; reliable GMP supply and defensible data secure the commercial relationship.
Market Dynamics
Drivers
The expanding pipeline of CAR-T, T-cell receptor, natural killer cell, stem-cell and regenerative therapies is the central demand engine. Every additional clinical program creates media consumption during process development, engineering runs, stability studies and patient-batch production. Approved products generate recurring use, while multicenter trials increase the number of collection and manufacturing events that require standardized preservation.
Decentralized and point-of-care production also raises the value of ready-to-use media. A process operated across hospitals or regional manufacturing sites needs fewer open manipulations and less operator-dependent compounding. Pre-formulated bags or vials with clear instructions can reduce preparation errors and improve consistency. The same logic supports use of defined media in closed, automated manufacturing platforms.
Regulatory scrutiny strengthens the shift to qualified materials. The U.S. FDA's May 2026 guidance on chemistry, manufacturing and controls flexibility for cell and gene therapies maintains the requirement to understand product and process risks even when development flexibility is available. Cryopreservation can affect stability and potency, so developers need evidence linking the chosen formulation and freeze-thaw procedure to product quality.
The commercial move toward allogeneic therapies adds a second growth pathway. Autologous manufacturing uses one patient batch at a time, while allogeneic production can create large banks and many finished doses from a donor or engineered cell line. These batches consume more media per run and place greater emphasis on scalability, bag formats, lot consistency and long-term supply agreements.
Restraints
Qualification timelines slow supplier conversion. A medium that performs well in research may still require months of testing before use in a clinical process. Developers must assess recovery, phenotype, potency, impurities, residual DMSO, container compatibility and stability. Programs already in late-stage development have little incentive to switch unless the current formulation presents a supply, quality or performance risk.
DMSO remains effective but creates clinical and operational concerns. Residual DMSO can contribute to infusion reactions, and exposure during formulation can harm sensitive cells. Reducing the concentration or replacing DMSO is not a simple formulation change because the revised medium must protect the relevant cell population throughout cooling, storage and thawing. The need for cell-specific validation limits rapid adoption of universal DMSO-free claims.
High-quality media carries a price premium over laboratory-prepared formulations. The direct media cost is small relative to a cell-therapy dose, yet early-stage companies still manage limited development budgets. Some programs delay the move to clinical-grade materials, creating a later comparability burden. Suppliers must therefore demonstrate how documentation, reduced preparation work and lower process risk offset the unit price.
Cold-chain failures can obscure media performance. Poorly controlled cooling, temperature excursions or inconsistent thawing may reduce cell recovery even when the formulation is suitable. Vendors need application support that connects the medium to the complete freeze-thaw workflow. Without that support, customers may incorrectly attribute a process failure to the product or carry an unsuitable protocol into scale-up.
Opportunities
Cell-specific media is a high-value development opportunity. CAR-T, CAR-NK, TIL, hematopoietic stem cells, mesenchymal stromal cells and iPSC-derived products differ in membrane behavior, cell concentration, final dose format and potency requirements. Suppliers that generate matched datasets across clinically relevant cell types can move beyond a generic catalog product and support higher-value qualification projects.
Ready-to-use large-volume bags can capture allogeneic and commercial production. They eliminate internal compounding steps and can connect directly to closed processing or fill-finish systems. Demand will increase for multiple bag sizes, weldable tubing, validated extractables and leachables, and robust shipping configurations. The media manufacturer may need to coordinate with bag, vial and automation vendors so the complete system remains compatible.
Regulatory-service packages provide another route to differentiation. Letters of authorization, master-file access, certificates of analysis, change-control notices, raw-material traceability and audit support shorten the customer's filing work. A supplier that maintains consistent documentation across regions can support a therapy moving from U.S. trials to European, Japanese and Asian sites.
Post-thaw optimization creates recurring service and consumable revenue. Thawing media, dilution solutions, automated thaw devices and validated protocols can be sold with the freezing formulation. The commercial proposition becomes control of the freeze-to-infusion transition rather than supply of one bottle. This approach can reduce cell loss during the most vulnerable handling steps.
Quantitative Market Segmentation
By Media Type
Serum-free and animal-origin-free formulations led the market with an estimated 68% share in 2025, representing USD 97.9 million. Their lead reflects adoption in clinical and commercial manufacturing, where developers need lower biological variability, traceable components and stronger regulatory documentation. Products formulated without serum or protein also reduce the need to qualify variable biological inputs. This segment is forecast to exceed 74% of revenue by 2035 as more programs standardize defined materials before pivotal studies.
FBS-containing and serum-supplemented formulations accounted for an estimated 22% of 2025 revenue, equal to USD 31.7 million. They remain common in academic research, early process development and established stem-cell protocols. Their share will decline as clinical translation exposes lot variability, sourcing and adventitious-agent concerns. Other customized and emerging media-including lower-DMSO, DMSO-free and cell-specific products-held 10%, or USD 14.3 million. This smaller category is expected to grow fastest when suppliers can prove post-thaw function in defined therapeutic cell populations.
By Cryoprotectant Strategy
DMSO-based media held an estimated 82% share in 2025, equal to USD 118.0 million. The segment includes formulations with 5% or 10% DMSO and retains its lead because DMSO is supported by extensive process experience across hematopoietic, immune and stem-cell workflows. Formulations using reduced DMSO or alternative cryoprotectants represented 18%, or USD 25.9 million. Their growth is supported by efforts to reduce toxicity and simplify post-thaw handling, but adoption depends on potency, stability and clinical comparability rather than composition alone.
By Cell-Therapy Application
Immune-cell therapy, including CAR-T, TCR-T, CAR-NK, TIL and related immunotherapies, accounted for an estimated 43% of revenue in 2025, equal to USD 61.9 million. Autologous programs create recurring patient-specific demand and strict chain-of-identity requirements, while allogeneic immune-cell platforms increase batch scale. Cryopreservation performance must protect cell viability, expansion capacity, phenotype and cytotoxic activity after thaw.
Hematopoietic stem-cell transplantation represented an estimated 22% share, or USD 31.7 million. This segment benefits from established freezing practices and routine use of DMSO-based solutions. Mesenchymal stromal and stem-cell therapies held 15%, equal to USD 21.6 million, while pluripotent and embryonic stem-cell applications generated 12%, or USD 17.3 million. Neural and other regenerative cell therapies accounted for the remaining 8%, or USD 11.4 million. Pluripotent and allogeneic immune-cell applications are forecast to post the strongest growth through 2035 because they rely on scalable master banks and standardized intermediate storage.
By End User
Pharmaceutical and biotechnology companies generated an estimated 57% of 2025 revenue, equal to USD 82.0 million. Their share reflects higher use of GMP-manufactured, documented media across clinical and commercial batches. Contract development and manufacturing organizations held 21%, or USD 30.2 million. CDMOs qualify materials across multiple customer processes and can influence vendor selection, making them important channel partners and technical gatekeepers.
Academic institutes, translational centers and research hospitals represented an estimated 15% share, equal to USD 21.6 million. Their purchasing is more fragmented and price-sensitive, but these groups establish early protocols that can carry into spinouts and clinical programs. Cell banks, cord-blood organizations and other users held 7%, or USD 10.1 million. Commercial biopharma and CDMO demand will gain share through 2035 as more programs advance into later-stage manufacturing.
Regional and Country-Level Analysis
North America led with an estimated 46% of global revenue in 2025, equal to USD 66.2 million. The United States alone represented 39%, or USD 56.1 million, supported by a large cell-therapy pipeline, commercial CAR-T manufacturing, specialized CDMOs and regulatory demand for controlled raw materials. Canada contributed 5%, equal to USD 7.2 million, with activity around regenerative medicine, iPSC translation and manufacturing clusters. The remainder of North America held 2%, or USD 2.9 million.
Europe accounted for an estimated 29% share, equal to USD 41.7 million. Germany generated 8% of global revenue, or USD 11.5 million, supported by bioprocess suppliers, research hospitals and advanced-therapy production. The United Kingdom held 6%, equal to USD 8.6 million, while France contributed 5%, or USD 7.2 million. Switzerland, Belgium, the Netherlands, Italy, Spain and other European markets together represented 10%, equal to USD 14.4 million. European buyers place strong weight on animal-origin status, pharmacopoeial compliance, material traceability and documentation that supports multinational trials.
Asia-Pacific represented an estimated 21% of revenue in 2025, equal to USD 30.2 million, and is forecast to record the fastest growth through 2035. China held 12% of the global market, or USD 17.3 million, driven by CAR-T development, domestic manufacturing capacity and a broad cell-therapy research base. Japan accounted for 7%, equal to USD 10.1 million, supported by regenerative-medicine development, iPSC programs and established bioprocess quality requirements. South Korea, Australia, Singapore, India and other Asian markets together held 2%, or USD 2.9 million. Regional suppliers will gain opportunities when they combine local availability with documentation acceptable for global clinical programs.
Latin America accounted for an estimated 2.5% of 2025 revenue, equal to USD 3.6 million, led by Brazil and Mexico. The Middle East and Africa held the remaining 1.5%, or USD 2.2 million, with demand concentrated in research institutions, transplant centers and selected biotechnology investments. These regions offer longer-term potential, but specialist distribution, cold-chain support and limited local clinical manufacturing constrain near-term revenue.
The country and regional figures measure revenue at the point of customer use. They are estimates based on therapeutic pipeline concentration, clinical-trial activity, manufacturing capacity, research infrastructure, supplier presence and adoption of qualified media. Regional totals reconcile to the USD 143.9 million global base.
Competitive Landscape
Competition centers on formulation performance, quality documentation, clinical references, supply reliability and technical support. BioLife Solutions has established a strong specialized position through CryoStor and related biopreservation products. Thermo Fisher Scientific competes through broad cell-therapy workflow integration and global commercial supply. Miltenyi Biotec connects freezing materials with cell-selection, processing, bags and closed manufacturing. PromoCell, STEMCELL Technologies, Merck, HiMedia Laboratories, Nippon Genetics, FUJIFILM Irvine Scientific and other suppliers address research-to-clinical needs through defined or specialized formulations.
The market is not won by catalog breadth alone. A therapy developer may test several products, but commercial selection favors evidence generated with the relevant cell type and process. Access to regulatory files, notification of manufacturing changes, multiple container formats and backup production capacity can protect a supplier's position after qualification. Smaller formulation specialists can compete effectively when they provide superior post-thaw potency or responsive application development.
Key Players
BioLife Solutions, Inc.; Thermo Fisher Scientific Inc.; Miltenyi Biotec B.V. & Co. KG; PromoCell GmbH; STEMCELL Technologies Inc.; Merck KGaA; HiMedia Laboratories; Nippon Genetics Co., Ltd.; FUJIFILM Irvine Scientific, Inc.; Sartorius AG; Lonza Group AG; and Biological Industries.
Detailed Company Profiles
BioLife Solutions, Inc.
BioLife Solutions is a specialist in biopreservation, cell processing, cryogenic storage and thawing technologies for cell and gene therapy. Its CryoStor range includes CS2, CS5 and CS10 formulations with different DMSO concentrations. CryoStor CS10 contains 10% DMSO and is serum-free and protein-free. The product is manufactured under cGMP conditions and supported by sterility, endotoxin and cell-based release testing, along with an FDA master file.
The company connects freezing media with HypoThermosol preservation media, CellSeal closed-system containers and ThawSTAR thawing products. This portfolio allows BioLife to address the complete freeze-store-thaw workflow and generate qualification support beyond the formulation itself. Its commercial position is reinforced by use of CryoStor in clinical cell-therapy programs and by regulatory-support materials for customer filings. In April 2026, BioLife reported that Sanguine Bio had standardized PBMC cryopreservation on CryoStor, providing a current example of workflow conversion.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific supplies freezing media through its Gibco portfolio and integrates these materials with cell-culture media, cytokines, cell-processing equipment and fill-finish systems. Relevant products include CTS Synth-a-Freeze Medium for clinical and commercial cell-therapy workflows, standard Synth-a-Freeze Cryopreservation Medium and Recovery Cell Culture Freezing Medium. The company's CTS framework focuses on materials manufactured with documentation suited to cell-therapy development.
Its competitive advantage is workflow breadth. A customer can source activation and expansion media, Dynabeads, recombinant proteins, Rotea cell processing and Compleo fill-finish technology through one supplier. This can simplify procurement and technical transfer, but each material still requires process-specific qualification. Thermo Fisher is positioning its media and equipment for closed, modular and automated manufacturing, aligning with the industry's effort to reduce open handling and operator variability.
Miltenyi Biotec
Miltenyi Biotec supplies cell-separation, activation, culture, manufacturing and cryopreservation products. Its CryoMACS range includes sterile DMSO and freezing bags for ex vivo cell processing. CryoMACS DMSO is produced under an ISO 13485 quality system and tested against European Pharmacopoeia requirements. The materials can be linked to the CliniMACS Prodigy platform and other MACS GMP products in closed cell-manufacturing workflows.
Miltenyi's market strength comes from its influence over the full therapeutic-cell process. Developers using CliniMACS technology can source related reagents, buffers, culture products and containers through the same organization. This creates opportunities to embed the freezing step in a validated process rather than sell it as a stand-alone consumable. The July 2026 launch of the European S.O.L.A.R.I.S. consortium to advance scalable CAR-T manufacturing supports the company's focus on connected manufacturing infrastructure.
PromoCell GmbH
PromoCell develops human cell-culture and cryopreservation products for research and translational applications. Cryo-SFM Plus is an animal-component-free, serum-free and protein-free medium supplied ready to use. The formulation contains 10% DMSO and is designed for mammalian cells, including sensitive primary and stem cells. The company also offers cell-specific culture media and primary human cells, which support matched workflow evaluation.
PromoCell competes through defined composition, application expertise, and accessibility to laboratories moving away from serum-containing recipes. Its position is strongest in preclinical and translational workflows where customers require repeatability and want a direct path from cell culture to preservation. The company can expand its commercial relevance by increasing GMP-aligned documentation, closed-container formats, and cell-therapy-specific validation data.
Recent Developments: March 15-September 15, 2026
- On September 1, 2026, STEMCELL Technologies published an ISSCR 2026 discussion on scaling iPSC-derived therapies. The session emphasized early consideration of manufacturing, quality control, automation, reimbursement, and regulatory strategy. For freezing-media suppliers, the practical implication is that preservation protocols and cell-bank materials must be designed for commercial scale before a program enters late development.
- In July 2026, Miltenyi Biotec announced the S.O.L.A.R.I.S. initiative to advance scalable CAR-T manufacturing across Europe. The program focuses on manufacturing infrastructure and access, creating a route for qualified freezing materials, bags, and closed processing solutions to be evaluated within standardized production workflows.
- In May 2026, the U.S. FDA issued final guidance describing CMC flexibilities for human cellular and gene therapy products developed for biologics license applications. The guidance does not remove the need to understand material and process controls. It raises the commercial value of suppliers that provide traceability, consistent manufacturing, change management and supporting regulatory documentation.
- On April 10, 2026, BioLife Solutions reported that Sanguine Bio standardized its PBMC preservation workflow on CryoStor. The adoption centers on consistent viability and cellular integrity after freezing and thawing. It demonstrates how a ready-to-use, defined medium can replace variable internal methods in biospecimen and translational workflows.
- On March 16, 2026, Sartorius launched the Eveo Cell Therapy Platform for automated, multi-parallel autologous manufacturing. Sartorius stated that one operator can process eight patient batches in the cleanroom space normally used for two, with first deliveries planned for 2027. Integration of raw materials, processing, fill formulation and quality control increases demand for media compatible with closed and automated workflows.
Market Outlook, 2026-2035
- Revenue is forecast to increase from USD 162.6 million in 2026 to USD 265.1 million in 2030 and USD 488.5 million in 2035. Growth will follow clinical manufacturing milestones rather than a smooth increase in laboratory consumption. A pivotal trial, commercial approval or a new allogeneic facility can create a step change in demand, while a failed program can remove an expected revenue stream.
- Serum-free media will capture most incremental value. The category aligns with regulatory control, reproducibility, and closed processing, and it provides a cleaner foundation for global filings. DMSO-based products will remain the volume standard, but lower-DMSO and alternative formulations will gain where developers demonstrate equal or better potency and manageable process economics.
- North America will remain the largest market through 2035 due to commercial production and pipeline depth. Asia-Pacific will narrow the gap as China, Japan, South Korea, and Singapore add advanced-therapy research and manufacturing. Local supply will matter more as customers seek shorter lead times and continuity, but global regulatory acceptance will prevent purely local price competition from determining clinical-material selection.
- The supplier landscape will divide into qualified platform products and application-specific solutions. Platform products will win programs seeking established regulatory support and broad clinical use. Specialized media will win when a cell population cannot tolerate a standard freeze-thaw process or when post-thaw potency provides a decisive advantage. In both cases, data, documentation and reliable supply will carry more commercial weight than formulation novelty alone.
